Matinas BioPharma Holdings (MTNB) Non Operating Income (2014 - 2020)
Matinas BioPharma Holdings (MTNB) posted quarterly Non Operating Income of $155093.0 for Q3 2020, down 1.13% year-over-year from $156872.0 in Q4 2019, and down 0.58% quarter-over-quarter from $156000.0 in Q2 2020.
Matinas BioPharma Holdings (MTNB) Non Operating Income (2014 - 2020) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Non Operating Income for 7 consecutive years, with $155093.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Non Operating Income fell 1.13% year-over-year to $155093.0; the TTM figure through Sep 2020 stood at $701572.0 (up 70.53% YoY), while the FY2019 annual figure was $541303.0, up 857.18% from the prior year.
- Non Operating Income eased to $155093.0 in Q3 2020 per MTNB's latest filing, from $156000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $227327.0 in Q1 2020 and bottomed at -$8893.0 in Q1 2017.
- Historically, Non Operating Income has averaged $60094.8 across 5 years, with a median of $13584.0 in 2017.
- Annual changes were most pronounced in 2016 — Non Operating Income sank 377.03% — and 2019, when it jumped 2867.94%.
- Matinas BioPharma Holdings' Non Operating Income stood at -$2402.0 in 2016, then surged by 461.28% to $8678.0 in 2017, then jumped by 283.13% to $33248.0 in 2018, then soared by 390.71% to $163152.0 in 2019, then dropped by 4.94% to $155093.0 in 2020.
- Business Quant data shows MTNB's Non Operating Income at $155093.0 in Q3 2020, $156000.0 in Q2 2020, and $227327.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 155,093.00 |
| Jun 30, 2020 | 156,000.00 |
| Mar 31, 2020 | 227,327.00 |
| Dec 31, 2019 | 163,152.00 |
| Sep 30, 2019 | 156,872.00 |
| Jun 30, 2019 | 168,872.00 |
| Mar 31, 2019 | 52,407.00 |
| Dec 31, 2018 | 33,248.00 |
| Sep 30, 2018 | 18,660.00 |
| Jun 30, 2018 | -6,101.00 |
| Mar 31, 2018 | 10,745.00 |
| Dec 31, 2017 | 8,678.00 |
| Sep 30, 2017 | 13,584.00 |
| Jun 30, 2017 | 8,663.00 |
| Mar 31, 2017 | -8,893.00 |
| Dec 31, 2016 | -2,402.00 |
| Sep 30, 2016 | -3,325.00 |
| Jun 30, 2016 | -3,656.00 |
| Mar 31, 2016 | -7,122.00 |
| Dec 31, 2015 | 19,715.00 |